Kollicoat® MAE 100-55 combines two things hard to bring together – it can directly exchange the comparable pH 5.5 enteric release coating polymer in your commercial formulations, and still bring significant handling improvement to your operators because it does not dust at all.

Kollicoat® MAE 100-55 is the latest addition to our comprehensive portfolio of functional excipients in our Instant & Modified Release Platform. It extends our offer of pH >5.5 enteric release products based on methacrylic acid-ethylacrylate copolymer, providing you even more flexibility.

<table>
<thead>
<tr>
<th>Kollicoat® MAE 100-55 (non-neutralized powder)</th>
<th>Kollicoat® MAE 100 P (pre-neutralized powder)</th>
<th>Kollicoat® MAE 30 DP (dispersion 30%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allows direct substitution in commercial formulations</td>
<td>No neutralization required</td>
<td>Most efficient and cost-effective (not spray-dried)</td>
</tr>
<tr>
<td>Aqueous &amp; organic coating</td>
<td>Suitable for extreme weather (powder)</td>
<td>Aqueous coating</td>
</tr>
<tr>
<td></td>
<td>Aqueous coating</td>
<td>Not suitable for freezing climate</td>
</tr>
</tbody>
</table>

No more dusting thanks to unique powder particle shape

The dry powder particles of Kollicoat® MAE 100-55 are larger and thus significantly less dusty than comparable 100-55 coating grades – much easier to work with for your operators.

Pharma Solutions.
Focusing on your needs with platform solutions.

Instant & Modified Release | Solubilization | Skin Delivery | Softgels | Biologic Solutions
Kollicoat® MAE 100-55
A complete match – just better.

Equivalent drug release
Despite its advantages in handling, Kollicoat® MAE 100-55 provides equivalent drug release as existing comparable coating grades in the market. And this means you can directly introduce it into your commercialized formulations.

![Graph showing equivalent drug release](image)

**Coated Bupropion HCl tablets (150mg);**
**N = 3; 50 rpm;**
**Buffer change after 2 h;**
**880ml HCl + 20 ml Tri-K phosphate**

Quality and regulatory status:
Kollicoat® MAE 100-55 is produced in Germany under GMP conditions. It complies to respective Ph.Eur., USP-NF and JPE monographs:

- **Ph.Eur.** Methacrylic Acid – Ethyl Acrylate Copolymer (1:1) Type A
- **USP/NF** Methacrylic Acid and Ethyl Acrylate Copolymer NF (revision Dec 1\textsuperscript{st}, 2015)
- **JPE** Dried Methacrylic Acid Copolymer LD

Talk to our experts:
- **Asia Pacific** Satish Moorkath  satish.moorkath@basf.com
- **North America** Suzanna Brown  suzanna.brown@basf.com
- **Europe** Peter Hoffmann  peter.wolfgang.hoffmann@basf.com
- **South America** Marien Oliveira  marien.oliveira@basf.com

BASF’s rich portfolio of instant and modified release solutions offers an unparalleled range of functionality. Our high quality, industry-leading products enable you to formulate pharmaceuticals with the exact release properties you desire. This ensures the right results every time – giving you that all-important competitive edge. BASF can help with Instant & Modified Release, Solubilization, Softgels, Skin Delivery and Biologics related formulation challenges.